Danaher (NYSE:DHR) Price Target Cut to $260.00 by Analysts at Evercore ISI

Danaher (NYSE:DHR) had its price objective decreased by Evercore ISI from $266.00 to $260.00 in a research report report published on Tuesday, Benzinga reports. Evercore ISI currently has an outperform rating on the conglomerate’s stock.

Several other research analysts have also issued reports on the company. Bank of America raised their target price on Danaher from $258.00 to $270.00 and gave the stock a neutral rating in a research report on Wednesday, April 24th. TD Cowen lifted their price objective on Danaher from $280.00 to $290.00 and gave the stock a buy rating in a research report on Wednesday, April 24th. HSBC raised Danaher from a hold rating to a buy rating and lifted their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. StockNews.com lowered Danaher from a buy rating to a hold rating in a research report on Tuesday, June 25th. Finally, Robert W. Baird lifted their price objective on Danaher from $259.00 to $271.00 and gave the stock an outperform rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $268.67.

Danaher Stock Down 1.7 %

Shares of NYSE:DHR opened at $240.41 on Tuesday. The firm has a market cap of $178.07 billion, a P/E ratio of 40.75, a P/E/G ratio of 3.82 and a beta of 0.84. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher has a 12-month low of $182.09 and a 12-month high of $269.11. The business has a fifty day simple moving average of $256.13 and a 200 day simple moving average of $246.86.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period last year, the company earned $2.36 EPS. Analysts predict that Danaher will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 in the last three months. Corporate insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Danaher

Hedge funds and other institutional investors have recently modified their holdings of the business. Tsfg LLC boosted its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. Cape Investment Advisory Inc. purchased a new position in Danaher in the fourth quarter valued at approximately $25,000. BKM Wealth Management LLC purchased a new position in Danaher in the fourth quarter valued at approximately $27,000. Redmont Wealth Advisors LLC purchased a new position in Danaher in the first quarter valued at approximately $30,000. Finally, Wetzel Investment Advisors Inc. purchased a new position in Danaher in the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.